

RUNX1 (Acetyl Lys24) rabbit pAb

Cat No.: ES20054

For research use only

Overview

Product Name RUNX1 (Acetyl Lys24) rabbit pAb

Host species Rabbit
Applications WB; ELISA

Species Cross-Reactivity Human; Mouse; Rat

Recommended dilutions WB 1:1000-2000 ELISA 1:5000-20000

Immunogen Synthesized peptide derived from human RUNX1

(Acetyl Lys24)

Specificity This antibody detects endogenous levels of

Human, Mouse, Rat RUNX1 (Acetyl Lys24)

Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and

0.02% sodium azide.

Storage Store at -20° C. Avoid repeated freeze-thaw cycles.

Protein Name RUNX1 (Acetyl Lys24)
Gene Name RUNX1 AML1 CBFA2

Cellular localization Nucleus.

Purification The antibody was affinity-purified from rabbit

antiserum by affinity-chromatography using

epitope-specific immunogen.

Clonality Polyclonal
Concentration 1 mg/ml
Observed band 50kD
Human Gene ID 861
Human Swiss-Prot Number Q01196

Alternative Names Runt-related transcription factor 1 (Acute myeloid

leukemia 1 protein;Core-binding factor subunit alpha-2;CBF-alpha-2;Oncogene AML-1;Polyomavirus

enhancer-binding protein 2 alpha B

subunit;PEA2-alpha B;PEBP2-alpha B;SL3-3 enhancer

factor 1 alpha B subunit

Background alternative products: Additional isoforms seem to

exist, caution: The fusion of AML1 with EAP in T-MDS induces a change of reading frame in the latter

resulting in 17 AA unrelated to those of



+86-27-59760950 ELKbio@ELKbiotech.com www.elkbiotech.com



EAP., disease: A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP, MSD1 or EVI1., disease: A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.,disease:A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1/MTG8/ETO., disease: A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP, MSD1 or EVI1., disease: A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H., disease: A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein., disease: Defects in RUNX1 are the cause of familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]. FPDMM is an autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.,domain:A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes., function: CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to



+86-27-59760950

ELKbio@ELKbiotech.com

www.elkbiotech.com



transactivate the mouse BLK promoter. Inhibits MYST4-dependent transcriptional activation., PTM: Methylated., PTM: Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with MYST3., similarity: Contains 1 Runt domain., subunit: Heterodimer with CBFB. RUNX1 binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization. Isoform AML-1L can neither bind DNA nor heterodimerize. Interacts with TLE1 and THOC4. Interacts with ELF1. ELF2 and SPI1. Interacts via its Runt domain with the ELF4 N-terminal region. Interaction with ELF2 isoform 2 (NERF-1a) may act to repress RUNX1-mediated transactivation. Interacts with MYST3 and MYST4. Interacts with SUV39H1, leading to abrogate the transactivating and DNA-binding properties of RUNX1., tissue specificity: Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood.,

